Pembrolizumab plus chemotherapy demonstrated improvement in progression-free survival versus chemotherapy in certain patients with metastatic triple-negative breast cancer in phase III KEYNOTE-355

Pembrolizumab reduced risk of disease progression/death by 35% (HR 0.65; 95% CI, 0.49-0.86, p=0.0012) and improved progression-free survival to median of 9.7 months vs. 5.6 months in chemotherapy group in patients whose tumours expressed PD-L1 with Combined Positive Score ≥10.


Biospace Inc.